The members of the Barron’s Roundtable see numerous bargains among health-care stocks. The conversations below are excerpted from our recent Midyear Roundtable, published on July 10. To read the entire Roundtable, click here.I have three health-care names. GlaxoSmithKline [ticker: GSK] yields almost 5% and offers single-digit organic earnings growth. Gilead Sciences [GILD] has a 3.
We expect Bristol-Myers to generate $41.8 billion of revenue this year, and earn about $6.20 a share, versus $4.69 in 2019. Revenue will get a one-time pop of about 60% because of last year’s acquisition of Celgene. For next year, we have modeled 7.5% revenue growth on the conservative side, or $45 billion, and earnings after taxes of $16.5 billion, or $7.33 a share. Using more-optimistic assumptions, the company could earn $17 billion, or $7.55 a share, on $45.6 billion of revenue.
$PFE
Big fan of $GILD
I think I'll buy some bread instead.
Ireland Ireland Latest News, Ireland Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: BusinessInsider - 🏆 729. / 51 Read more »
Source: BusinessInsider - 🏆 729. / 51 Read more »